about
The emerging role of oxylipins in thrombosis and diabetesThe Efficacy and Clinical Safety of Various Analgesic Combinations for Post-Operative Pain after Third Molar Surgery: A Systematic Review and Meta-AnalysisThe association of four common polymorphisms from four candidate genes (COX-1, COX-2, ITGA2B, ITGA2) with aspirin insensitivity: a meta-analysisInhibition mechanism of the intracellular transporter Ca2+-pump from sarco-endoplasmic reticulum by the antitumor agent dimethyl-celecoxibNovel non-cyclooxygenase inhibitory derivatives of naproxen for colorectal cancer chemopreventionHepatic ischemia and reperfusion injury in the absence of myeloid cell-derived COX-2 in mice.2-(2-Arylphenyl)benzoxazole As a Novel Anti-Inflammatory Scaffold: Synthesis and Biological EvaluationExpression of integrin α3β1 and cyclooxygenase-2 (COX2) are positively correlated in human breast cancerSubstrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentationLongterm blood pressure variability in patients with rheumatoid arthritis and its effect on cardiovascular events and all-cause mortality in RA: a population-based comparative cohort study.Safety of nonsteroidal antiinflammatory drugs in patients with cardiovascular disease.Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?Time course change of COX2-PGI2/TXA2 following global cerebral ischemia reperfusion injury in rat hippocampus.15-Deoxy-Δ12,14-prostaglandin J2 inhibits macrophage colonization by Salmonella enterica serovar Typhimurium.Hypoxia-inducible factor-2α is essential in activating the COX2/mPGES-1/PGE2 signaling axis in colon cancer.Cyclooxygenase-1 and prostacyclin production by endothelial cells in the presence of mild oxidative stress.Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.PET imaging of cyclooxygenase-2 (COX-2) in a pre-clinical colorectal cancer model.Lipoxygenase: an emerging target for stroke therapyDiscovery and characterization of carbamothioylacrylamides as EP2 selective antagonists.Serious Non-AIDS events: Immunopathogenesis and interventional strategies.Constitutive activation of AMPK α1 in vascular endothelium promotes high-fat diet-induced fatty liver injury: role of COX-2 induction.Aging dysregulates D- and E-series resolvins to modulate cardiosplenic and cardiorenal network following myocardial infarction.Gastroprotective [6]-Gingerol Aspirinate as a Novel Chemopreventive Prodrug of Aspirin for Colon Cancer.Valdecoxib : the rise and fall of a COX-2 inhibitor.Cyclooxygenase-2 Mediated Oxidation of 2-Arachidonoyl-Lysophospholipids Identifies Unknown Lipid Signaling Pathways.Aspirin resistance and other aspirin-related concerns.Management of NSAID-associated peptic ulcer disease.Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV InfectionHierarchical Models for Multiple, Rare Outcomes Using Massive Observational Healthcare Databases.Design, Synthesis, and Evaluation of an (18)F-Labeled Radiotracer Based on Celecoxib-NBD for Positron Emission Tomography (PET) Imaging of Cyclooxygenase-2 (COX-2).Monoglyceride lipase as a drug target: At the crossroads of arachidonic acid metabolism and endocannabinoid signaling.Maintenance of GLUT4 expression in smooth muscle prevents hypertension-induced changes in vascular reactivity.A genomic exploration identifies mechanisms that may explain adverse cardiovascular effects of COX-2 inhibitors.Inhibition of microsomal prostaglandin E synthase-1 by aminothiazoles decreases prostaglandin E2 synthesis in vitro and ameliorates experimental periodontitis in vivo.Aminothiazoles inhibit RANKL- and LPS-mediated osteoclastogenesis and PGE2 production in RAW 264.7 cells.Non-steroidal anti-inflammatory drugs attenuate the vascular responses in aging metabolic syndrome rats.The read-across hypothesis and environmental risk assessment of pharmaceuticals.Effect of PGE2-EPs pathway on primary cultured rat neuron injury caused by aluminum.Indomethacin on extra-cranial cerebral arterial vasomotion: beyond cyclooxygenase-prostaglandin inhibition.
P2860
Q26823893-2DBABF9B-0079-4ADD-8C0B-A512C0AF86B5Q26860726-3E0F9E97-7A7E-415D-A736-6AF4BD5A1563Q26860958-96E7C94D-4396-4B5D-9F54-7109EC5CA282Q28540515-329A1888-BB28-4AA2-9828-87CF559BF9B8Q28829463-AFCFC19C-258C-49D2-991E-DF019166AC96Q33600026-E0C530F0-8E4C-49DD-B622-00C9866EAB29Q33636453-A08DF5DF-C753-44EB-8849-45856969F1C0Q33801546-A95D7AFE-2676-4C45-B922-3024DB5BEC34Q33819279-60AFC793-1D94-428D-94A1-3CBD479A952FQ34157718-E00F4EAE-4C2E-437F-942F-BABF02A754C6Q34474985-34B7ACDB-5ADC-4A9A-BB98-E6DFC78FF3C2Q34494513-5D938E2F-CA53-43A8-B5C2-8E35DCFF76B8Q34558658-FD35260D-2BC4-46EB-8DA8-C6D49747115CQ34903814-14963513-12E5-4BFE-9E96-3BF09E7AAB46Q36499761-B05C6436-A09F-4176-8695-05115DAD42FAQ36618741-9C207934-F045-4743-A66B-5202EA0FE8CEQ36833728-4738223A-2729-49BE-982D-34C713654946Q36834358-0306EB9B-2975-4B55-BEBA-115F9E870FA3Q36913914-7BBF1C7E-D417-4A46-8C46-EC0446260ABCQ37063800-C6F1FC8A-B9B2-4493-9953-46F1E381F1BFQ37418140-09455DB9-4453-430E-B7F5-8F5165C8B57DQ37522889-DADE8DB0-3075-4D2A-966B-1342284CDD8CQ37538163-55FC8D8B-BBE3-4D0C-8E97-D3D2559040A0Q37571099-B6C6FEB3-A6FF-4F67-B5DF-8CD3DFC4F231Q38091707-B871CFA9-5690-47C2-8466-5FCC2868AAFAQ38409622-4501B279-52C4-4B6F-8AE3-1D69759BEAD3Q38634815-68AFC8EA-C1F3-4610-B212-3901CE0E5761Q38699305-27F40F12-2908-43F5-85DA-B57ABE205244Q38749963-FF20C5BC-2432-42A4-A692-1A6B1B06C96FQ38786754-CA53FF76-75FD-4456-8D54-B793BE9CED41Q38842627-E5B744C6-D20A-4F5D-A5D1-6B0CAAD4776AQ39141240-D5FFF9C3-EA0F-4BD6-9903-622860DF5010Q39509692-4E5B1CD9-44FF-48BA-B6FC-D748C8270F48Q40062073-C3F0192E-59AE-4409-A9D7-7FF76A931567Q40870546-02D8AA43-A74A-4367-B450-0849E181B02DQ41898452-3FD3AC00-D6FE-4889-9F62-977288DD49E6Q42263009-EE0BCC1C-8DA4-45F1-A94C-19EF0B3F4CF7Q42792319-D0483D8E-0179-427A-8966-40EDF3D5FCF6Q46901630-3854BF99-9F18-442E-919A-332212BA14A5Q48346480-D33178E1-97B5-4C39-9DA9-3DAC6F25EE1C
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Physiology. COX-2 inhibitors and cardiovascular risk.
@ast
Physiology. COX-2 inhibitors and cardiovascular risk.
@en
Physiology. COX-2 inhibitors and cardiovascular risk.
@nl
type
label
Physiology. COX-2 inhibitors and cardiovascular risk.
@ast
Physiology. COX-2 inhibitors and cardiovascular risk.
@en
Physiology. COX-2 inhibitors and cardiovascular risk.
@nl
prefLabel
Physiology. COX-2 inhibitors and cardiovascular risk.
@ast
Physiology. COX-2 inhibitors and cardiovascular risk.
@en
Physiology. COX-2 inhibitors and cardiovascular risk.
@nl
P2860
P356
P1433
P1476
Physiology. COX-2 inhibitors and cardiovascular risk.
@en
P2093
Christopher P Cannon
Paul J Cannon
P2860
P304
P356
10.1126/SCIENCE.1224398
P407
P577
2012-06-01T00:00:00Z